Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promethean Health CBD for mild to moderate non-palliative pain
ACTRN12623000404628Phase 3Recruiting
- Sponsor
- Promethean Health
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pain comparing Promethean Health CBD with Placebo (2 arms). Primary endpoint: Mean change from baseline in BPI-SF pain severity score on Day 30. Started Jul 2023; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
pain
Beyond the preview
Go deeper on ACTRN12623000404628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000404628.